## MO: Altria Group, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 4.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($55.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Silver Oak Securities Incorporated Boosts Stock Position in Altria Group, Inc. $MO**
- Source: MarketBeat | 20260102T120328 | Somewhat-Bullish | Relevance: 100%
- Silver Oak Securities Incorporated significantly increased its holdings in Altria Group, Inc. (NYSE:MO) by 155.4% during the third quarter, bringing their total to 31,220 shares valued at $2,062,000. Several other institutional investors also adjusted their positions in Altria, which currently has a market capitalization of $96.81 billion and an annualized dividend yield of 7.4%. The company recently declared a quarterly dividend of $1.06 and announced a $2.00 billion share buyback program.

**2. Goldman Sees Growth Catalyst for Altria Group, Inc. (MO) After FDA Approval of on! PLUS**
- Source: Yahoo Finance Singapore | 20260102T211511 | Bullish | Relevance: 100%
- Goldman Sachs analyst Bonnie Herzog identified the FDA's marketing authorization for six of Altria Group, Inc.'s on! PLUS nicotine pouch products as a significant growth catalyst. This regulatory milestone supports Altria's "Moving Beyond Smoking" strategy and positions the company to expand its high-margin oral nicotine portfolio while enhancing competitiveness against rivals. Another analyst, Lisa Lewandowski of BofA Securities, maintained a Buy rating on MO but lowered the price target due to evolving consumer trends and pressure from the illicit e-vapor market.

**3. Goldman Sees Growth Catalyst for Altria Group, Inc. (MO) After FDA Approval of on! PLUS**
- Source: Insider Monkey | 20260102T210808 | Somewhat-Bullish | Relevance: 100%
- Goldman Sachs analyst Bonnie Herzog identified a significant growth catalyst for Altria Group (MO) following the FDA's marketing authorization for six of its on! PLUS nicotine pouch products. This approval, which is the first under a new expedited PMTA pilot program, supports Altria's "Moving Beyond Smoking" strategy by enhancing its oral nicotine portfolio. While boosting Altria's competitiveness, BofA Securities maintained a Buy rating but lowered the price target due to evolving consumer trends and pressure from the illicit e-vapor market.

**4. Altria: A Turnaround Stock For 2026 (Rating Upgrade) (NYSE:MO)**
- Source: Seeking Alpha | 20260102T152900 | Bullish | Relevance: 100%
- Altria presents a compelling turnaround opportunity for 2026, driven by leadership transition, regulatory wins, and an expanded $2.0B stock buyback program. The company is poised to pay out approximately 76% of its adjusted EPS in 2026 and is expanding into smoke-free products. With a valuation of just 10.5X forward earnings, Altria offers a ~10% earnings yield and a 7.2% forward dividend yield, positioning it for potential recovery to pre-Q3 price levels.

**5. VIRGINIA RETIREMENT SYSTEMS ET Al Has $139.96 Million Position in Altria Group, Inc. $MO**
- Source: MarketBeat | 20251231T115459 | Neutral | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in Altria Group, Inc. by 1.8% in the third quarter, bringing its total holdings to 2,118,700 shares valued at $139.96 million. Other institutional investors like Vanguard Group Inc. and TigerOak Management L.L.C. also adjusted their positions. Altria Group recently reported strong quarterly earnings, approved a $2.00 billion stock repurchase program, and declared a quarterly dividend of $1.06 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.5% (-0.4%)
- Blackrock Inc.: 7.5% (+2.4%)
- State Street Corpora: 4.3% (-0.9%)
- Charles Schwab Inves: 3.5% (-4.7%)
- Geode Capital Manage: 2.7% (+1.2%)

### Key Risks

1. Valuation stretched: PEG 4.0x requires aggressive growth execution.
2. Long-term trend broken: trading 5.6% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.01 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x stretched relative to 3% growth. Quality metrics strong (ROA 22%, margin 44%). Balance sheet: $3.0B free cash flow. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $96.3B |
| Beta | 0.50 |
| 52W Range | $50.08 - $68.60 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.01 |
| Forward P/E | 10.3 |
| Current P/E | 10.5 |
| YoY Growth | 2.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.9% to 0.1% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Below SMA200 (0.94x), long-term trend not supportive. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.12% (CS: 40) | Neutral |
| RSI_14 | 37.6 | Neutral |
| MACD Histogram | -0.07 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.944x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $57.31
- **Stop Loss:** $55.87 (2.5% risk)
- **Target:** $58.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 833
- **Position Value:** $47,739.23
- **Portfolio %:** 47.74%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-29 (Est: $1.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.45 | $1.45 | +0.1% |
| 2025Q2 | $1.38 | $1.44 | +4.0% |
| 2025Q1 | $1.19 | $1.23 | +3.5% |
| 2024Q4 | $1.28 | $1.29 | +0.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*